Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Tian C, Liu J, Zhou H, Li J, et al. Cancer Lett 2021;518:49-58.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tian C, Liu J, Zhou H, Li J, et al. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Lett 2021;518:49-58.
PMID: 34139284